Results 21 to 30 of about 26,841 (202)
Haematologica, 2021 Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessing this
Vincent Jachiet +27 more
doaj +1 more source
Platelets, 2021 Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with
Simone Birocchi +4 more
doaj +1 more source
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Introduction Deep brain stimulation (DBS) is an effective treatment for refractory obsessive–compulsive disorder (OCD). Neuropsychological assessment contributes to DBS treatment in several ways: it monitors the cognitive safety of the treatment, identifies beneficial or detrimental cognitive side effects and it could aid to explain ...
Tim A. M. Bouwens van der Vlis +7 more
wiley +1 more source
Thrombocytopenia induced by clopidogrel: a rare adverse effect
European Journal of Case Reports in Internal Medicine, 2023 Introduction: Immune thrombocytopenic purpura (ITP) can be induced by several drugs but there are few case reports of ITP induced by clopidogrel. Second-line treatment with thrombopoietin receptor agonists (TPO-RA) presents solid evidence and should be ...
Catarina Távora +2 more
doaj +1 more source
Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP
British Journal of Haematology, 2023 SummaryImmune thrombocytopenia (ITP) is a disorder characterized by low platelets due to increased clearance and decreased platelet production. While ITP has been characterized as an acquired disorder of the adaptive immune system, the resulting platelet autoantibodies provide ancillary links to the innate immune system via antibody interaction with ...
Ilene Ceil Weitz, Howard Allen Liebman
openaire +2 more sources
Lenalidomide-Associated ITP [PDF]
Case Reports in Hematology, 2011 Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described.
Christina I. Herold +2 more
openaire +3 more sources
Journal of Blood Medicine, 2021 Fei Song,1,2 Hanny Al-Samkari2,3 1Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA; 3Division of Hematology, Massachusetts General Hospital, Boston, MA, USACorrespondence: Hanny Al ...
Song F, Al-Samkari H
doaj
Treatment of Chronic ITP [PDF]
Pediatric Hematology and Oncology, 1995 [Abstract Not Available]
openaire +2 more sources
Use of rituximab for treatment of HIV-infected patients with hematological disorders
Клиническая онкогематология, 2013 Rituximab (MabThera) is one of the most powerful drug with selective action on B-cells. The drug suppresses the polyclonal antibody response to own antigens in autoimmune diseases. For lymphatic tumors it selectively acts on tumors of B-cells.
A. V. Pivnik
doaj +1 more source
Numerical and Experimental Study of Flutter in a Realistic Labyrinth Seal
International Journal of Turbomachinery, Propulsion and PowerLabyrinth seals are commonly used in turbomachinery in order to control leakage flows. Flutter is one of the most dangerous potential issues for them, leading to High Cycle Fatigue (HCF) life considerations or even mechanical failure.
Oscar Bermejo +5 more
doaj +1 more source